[Formation of neutralizing antibodies in therapy of multiple sclerosis with interferon beta-1b. Practical procedure in suspected therapeutic failure].
Interferon beta-1b has been shown to reduce the frequency and severity of exacerbations in relapsing-remitting multiple sclerosis (MS). In the North American study, however, approximately 35% of patients developed neutralizing antibodies leading to a diminution of therapeutic efficacy according to current investigations. In contrast, antibody-negative patients showed a 50% reduction in the annual relapse rate compared to patients receiving placebo. Here we provide practical guidelines for neutralizing antibody testing if treatment failure is suspected.
Walther
E U
EU
Neurologische Klinik und Poliklinik, Klinikum Grosshadern, Ludwig-Maximilians-Universität, München.
Dang
T
T
Hartung
H P
HP
Hohlfeld
R
R
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects; D000917:Antibody Formation / Q000276:immunology*; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D009460:Neurologic Examination / Q000187:drug effects; D009500:Neutralization Tests; D017211:Treatment Failure
D000276:Adjuvants, Immunologic; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a
Bildung von neutralisierenden Antikörpern unter Therapie der multiplen Sklerose mit Interferon beta-1b. Praktisches Vorgehen bei Verdacht auf Therapieversagen.